264254-32-2

Basic information

• Product Name: (3R,3'R,6'R)-β,ε-carotenyl-3,3'-disuccinate
• Synonyms: (3R,3'R,6'R)-β,ε-carotenyl-3,3'-disuccinate
• CAS NO: 264254-32-2
• Molecular Weight: 769.031
• Mol File: 264254-32-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (3R,3'R,6'R)-β,ε-carotenyl-3,3'-disuccinate(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,3'R,6'R)-β,ε-carotenyl-3,3'-disuccinate(264254-32-2)
• EPA Substance Registry System: (3R,3'R,6'R)-β,ε-carotenyl-3,3'-disuccinate(264254-32-2)

Safety Data

• Hazardous Substances Data: 264254-32-2(Hazardous Substances Data)

Upstream product

• 108-30-5 succinic acid anhydride 
• 127-40-2 lutein 

Downstream Products

• 1355481-26-3 C₈₀H₁₂₈O₂₄ 
• 1355481-68-3 C₆₄H₉₆O₁₆ 

Relevant articles and documents

Synthesis of lutein esters using a novel biocatalyst of: Candida antarctica lipase B covalently immobilized on functionalized graphitic carbon nitride nanosheets

Lutein scavenges free radicals and inhibits vision damage caused by photo oxidation, while decomposing easily with light and heat. Its stability and bioavailability can be tremendously improved by lutein ester synthesis. However, green and efficient ester

Dicarotenoid esters of bivalent acids

For the evaluation of the synthesis of dendritic esters from carotenoids the C20 apocarotenoid retinol was chosen for model studies, being a commercially available hydroxy carotenoid. Dimers were synthesized from retinol with dicarboxyl cores and from retinol succinate with other hydroxy carotenoids.

CAROTENOIDS, CAROTENOID ANALOGS, OR CAROTENOID DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

A method and system used for treating proliferative disorders using carotenoids, carotenoid analogs, and/or carotenoid derivatives. The method and system may be used for chemoprevention and/or chemotherapy. The method and system may induce apoptosis in target cells, tissues, and/or organs. The analog, derivative, or intermediate may be administered to a cell, a group of cells, a tissue, an organ or a subject, such that at least a portion of the undesirable consequences of the proliferative disorder are thereby reduced.